WO2019225845A1 - Composition pour soulager le méningiome en utilisant le salidroside et la bétuline - Google Patents

Composition pour soulager le méningiome en utilisant le salidroside et la bétuline Download PDF

Info

Publication number
WO2019225845A1
WO2019225845A1 PCT/KR2019/003096 KR2019003096W WO2019225845A1 WO 2019225845 A1 WO2019225845 A1 WO 2019225845A1 KR 2019003096 W KR2019003096 W KR 2019003096W WO 2019225845 A1 WO2019225845 A1 WO 2019225845A1
Authority
WO
WIPO (PCT)
Prior art keywords
betulin
composition
meningioma
salidroside
cells
Prior art date
Application number
PCT/KR2019/003096
Other languages
English (en)
Korean (ko)
Inventor
김예원
김정열
Original Assignee
Kim Ye Won
Kim Jung Yeal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kim Ye Won, Kim Jung Yeal filed Critical Kim Ye Won
Publication of WO2019225845A1 publication Critical patent/WO2019225845A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention

Definitions

  • the present invention relates to a composition for improving meningioma, comprising salidroside of Formula 1 below or betulin of Formula 2 as an active ingredient.
  • Cancer is a life-threatening disease in which abnormal cells multiply indefinitely and spread throughout the body (LifeSciencePublishing Co. 2008. p3-49). Cancer accounts for about 20% of deaths worldwide (World HealthOrganization.Geneva. 2012. Switzerland.p80-81) and is the number one cause of death from 1983 to 2011 in Korea (National Statistical Office 2012). For this reason, various studies on cancer prevention have been conducted (PNAS. 1995. 92 (12): 5258-5265; JAMA. 1996. 276 (24): 1957-1963; NEJM.1996. 334 (18): Food Science and Industry 1150-1155. 1997. 30 (1): 59-63).
  • the MTT assay is a method that utilizes the characteristic that living cells reduce MTT using mitochondrial dehydrogenase to form blue formazan crystals that can be measured spectrophotometrically. It was designed to analyze the degree of proliferation by mitogen, but recently it has been modified and used as a method for assessing the sensitivity of anticancer drugs to tumor cell lines (Cancer Res. 1987 Nov 15. 47 (22): 5875-9; Cancer Res. 1987 Feb 15. 47 (4): 943-6).
  • Salidroside is a substance in which glucose is an ester bond of hydroxy group of tyrosol and is also called rhodioloside. It is known as a therapeutic agent for degenerative nervous system diseases by preventing cardiovascular disease, protecting brain cell damage, protecting and regenerating nerve cells, and regulating neurotransmitters (Phytother Res. 2012. 26 (6): 878-83) . In addition, the compound has been studied to inhibit the irradiation of bone cells by acting on the formation and development of bone cells (PLoS One. 2013. 8 (2): e57251).
  • Betulin has been published in the literature has been widely used as a raw material used in the organic synthesis of betulinic acid (betulinic acid), betulinic acid (betulonic acid) or derivatives thereof useful as a therapeutic agent (therapeutic agent).
  • betulinic acid has anticancer activity against melanoma (e.g., MEL-2, MEL-2 and MEL-4) (Nat Med. 1995 Oct; 1 (10): 1046-51) and betulinic acid in humans.
  • MEL-2, MEL-2 and MEL-4 e.g., MEL-2, MEL-2 and MEL-4
  • H9 cells which are lymphoma cells, have anti-HIV activity (J Nat Prod. 1994. 57 (2): 243-7).
  • betulin was used in combination with acyclovir, and antiviral effects were reported for herpessimplex viruses (Antiviral Res. 2004. 64 (2): 127-30). In addition, clinical studies show that betulin can induce cell death in some types of tumor cells and delay the growth of several types of tumor cells (Eur J Pharm Sci. 2006. 29 (1): 1-13).
  • the present invention discloses the activity of meningioma using salidroside and / or betulin having cytotoxicity against HBL-52 cells, which are human-derived meningioma cell lines.
  • An object of the present invention is to provide a composition for improving meningioma using salidroside (Salidroside) and / or betulin (Betulin).
  • the present invention is a concentration-dependent cell proliferation when Salidroside (Salidroside) and / or Betulin (Betulin) is treated by concentration to HBL-52 cells, which are human-derived meningioma cells, as confirmed in the Examples below IC 50 , a concentration that inhibits cell proliferation by 50%, was found to be 25.2, 8.8 and 2.3 ⁇ g / mL, respectively, and it was confirmed that the effect of inhibiting cell proliferation was higher than that of a single treatment group when mixed with salidroside and betulin. In view of the low IC 50 value, it was confirmed that there is a combination effect than a single material.
  • the present invention provides a compound selected from the group consisting of (i) Salidroside of Formula 1 below, an isomer thereof, a prodrug thereof, a hydrate thereof, and a solvate thereof, (ii) a compound selected from the group consisting of Betulin, an isomer thereof, a prodrug thereof, a hydrate thereof, and a solvate of Formula 2, below; It can be grasped as a composition for improving meningioma using a mixture of compounds as an active ingredient.
  • isomers are not only essentially pure diastereomers, including optical isomers, but also conformational isomers, position isomers (especially tautomers or geometric isomers) or geometric isomers.
  • geometric isomers eg, cis-trans isomers.
  • prodrug refers to a drug that does not show physiological activity by itself but can exert its effect by changing to the original drug by chemical or enzymatic action in the body after administration. Manufactured for the purpose of controlling physical and chemical properties. In some cases prodrugs may be used to make administration easier. For example, some drugs do not ferment the drug by oral administration, but the prodrug may ferment the drug by oral administration. Prodrugs may also be prepared to increase the solubility of the drug. For example, prodrugs may be in the form of esters that facilitate the passage of cell membranes, where the water solubility is detrimental to mobility but once hydrolyzed is hydrolyzed to the active carboxylic acid by metabolism. Another example of a prodrug may be a short peptide that is bound to an acid group that is converted by metabolism to reveal the active site.
  • hydrate refers to a compound to which water is bound, and includes a compound containing no chemical bonding force between water and the compound.
  • the hydrate may contain 1 equivalent or more, preferably 1 to 5 equivalents of water.
  • Such hydrates can be prepared by crystallizing the compounds of the present invention, their pharmaceutically acceptable salts, or isomers thereof from water or a solvent containing water.
  • solvate means the compound which generate
  • Such solvates may include stoichiometric or nonstoichiometric amounts of solvent that are bound by non-covalent intermolecular forces.
  • Preferred solvents may be ethanol, methanol, propanol, methylene chloride, and the like, which are non-volatile and do not exhibit more toxic to humans.
  • the "active ingredient” means a component that can exhibit the desired activity alone or in combination with a carrier which is itself inactive.
  • meningio meningioma improvement is meant to include induction of death of meningioma cells or inhibition of their proliferation, thereby suppressing recurrence of meningiomas.
  • the composition of the present invention may include the active ingredient in any amount (effective amount) as long as it can exhibit the effect of treating and improving meningioma disease intended to be treated according to the use, formulation, formulation purpose, etc. It will be determined within the range of 0.001% to 15% by weight based on the total weight of the composition.
  • the term “effective amount” herein refers to a mammal, preferably to a human subject, when a composition of the present invention is administered to a human being by the suggestion of a medical professional or the like for a disease involving muscle growth effect, exercise ability improvement effect, and muscle loss. It refers to the amount of the active ingredient included in the composition of the present invention, which can exhibit the intended medical and pharmacological effects such as an improvement effect. Such effective amounts can be determined experimentally within the range of ordinary skill in the art.
  • the present invention can be understood as a pharmaceutical composition in specific embodiments.
  • compositions of the present invention may be prepared in oral or parenteral formulations according to the route of administration by conventional methods known in the art, including pharmaceutically acceptable carriers in addition to the active ingredient.
  • the route of administration here can be any suitable route, including the topical route, the oral route, the intravenous route, the intramuscular route, and direct absorption through mucosal tissue, and may be used in combination of two or more routes.
  • An example of a combination of two or more routes is where a drug of two or more formulations according to the route of administration is combined, for example when one drug is administered first by the intravenous route and the other by the local route.
  • Pharmaceutically acceptable carriers are well known in the art depending on the route of administration or formulation, and specific reference may be made to the pharmacopoeia of each country, including "Korea Pharmacopoeia.”
  • composition of the present invention is prepared in an oral dosage form, powders, granules, tablets, pills, dragees, capsules, solutions, gels, syrups, suspensions, wafers according to methods known in the art with suitable carriers It may be prepared in a formulation such as.
  • suitable carriers include lactose, glucose, sucrose, dextrose, sorbitol, sugars such as mannitol, xylitol, starch such as corn starch, potato starch, wheat starch, cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, Celluloses such as hydroxypropylmethylcellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, magnesium stearate, mineral oil, malt, gelatin, talc, polyol, vegetable oil, ethanol, and Cerrol etc. are mentioned.
  • binders include starch, magnesium aluminum silicate, starch ferrite, gelatin, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone, glucose, corn sweeteners, sodium alginate, polyethylene glycol, waxes, and the like.
  • the disintegrating agents include starch, methyl cellulose And agar, bentonite, xanthan gum, starch, alginic acid or its sodium salt and the like.
  • lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, glycine etc. are mentioned as a diluent.
  • compositions of the present invention When the pharmaceutical compositions of the present invention are prepared in parenteral formulations, they may be formulated in the form of injections, transdermal administrations, nasal inhalants and suppositories with suitable carriers according to methods known in the art.
  • a suitable carrier may be an aqueous isotonic solution or suspension.
  • an isotonic solution such as phosphate buffered saline (PBS) containing triethanol amine, sterile water for injection, or 5% dextrose may be used.
  • PBS phosphate buffered saline
  • transdermal administration it may be formulated in the form of an ointment, cream, lotion, gel, external solution, pasta, linen, aerosol, and the like.
  • Nasal inhalants can be formulated in the form of aerosol sprays using suitable propellants, such as dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, etc. witepsol), tween 61, polyethylene glycols, cacao butter, laurin paper, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearate, sorbitan fatty acid esters and the like.
  • suitable propellants such as dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, etc. witepsol
  • tween 61 polyethylene glycols, cacao butter, laurin paper, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearate, sorbitan fatty acid esters and the like.
  • compositions of the present invention may be formulated into suitable formulations with acceptable pharmaceutical carriers and administered by a variety of routes.
  • Administration means introducing a predetermined substance into a patient in any suitable way and the route of administration of the composition can be administered via any general route as long as it can reach the desired tissue. Intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, nasal administration, pulmonary administration, rectal administration, but is not limited thereto. However, upon oral administration, since the peptide is digested, it is desirable to formulate the oral composition to coat the active agent or to protect it from degradation in the stomach.
  • the pharmaceutical composition may be administered by any device that allows the active substance to migrate to the target cell.
  • Injectables include non-aqueous solvents such as aqueous solvents such as physiological saline solution and ring gel solution, vegetable oils, higher fatty acid esters (e.g., oleic acid, etc.), and alcohols (e.g., ethanol, benzyl alcohol, propylene glycol, glycerin, etc.).
  • Stabilizers e.g.
  • ком ⁇ онентs such as mercury nitrate, chimerosal, benzalkonium chloride, phenol, cresol, benzyl alcohol, and the like.
  • Preferred dosages of the pharmaceutical compositions of the present invention are the type of disease, age, weight, health, sex of the patient, sensitivity to the drug of the patient, route of administration, method of administration, frequency of administration, duration of treatment, combination or drug used concurrently. It can be easily determined by those skilled in the art according to factors well known in the medical field.
  • the active substance can be administered at a dose of 0.001 mg / kg to 10 g / kg per day, preferably 0.001 mg / kg to 1 g / kg. Administration can be done once a day or divided into several times. Such dosage should not be construed as limiting the scope of the invention in any aspect.
  • this invention can be understood as a food composition.
  • the food composition of the present invention may be prepared in any form, for example, beverages such as tea, juice, carbonated beverages, ionic beverages, processed oils such as milk, yogurt, gums, rice cakes, sweets, bread, sweets, noodles, and the like. It can be prepared as a dietary supplement, such as foods, tablets, capsules, pills, granules, liquid, powder, flaky, paste, syrup, gel, jelly, bar. In addition, the food composition of the present invention can distinguish any product as long as it conforms to the enforcement regulations at the time of manufacture and distribution in the legal and functional divisions.
  • beverages such as tea, juice, carbonated beverages, ionic beverages, processed oils such as milk, yogurt, gums, rice cakes, sweets, bread, sweets, noodles, and the like. It can be prepared as a dietary supplement, such as foods, tablets, capsules, pills, granules, liquid, powder, flaky, paste, syrup, gel, jelly, bar.
  • the food composition of the present invention can distinguish any product as long as it conform
  • it is a health functional food according to the Act on Health Functional Foods, or confectionary, soybeans, soy milk, fermented beverages, special purpose foods according to each food type in the Food Code of the Food Sanitation Act (KFDA Notification, Food Standards and Standards). In particular, the weight control preparation) and the like.
  • the food composition of the present invention may include food additives in addition to the active ingredient.
  • Food additives are generally understood as substances that are added to foods, mixed or infiltrated in the manufacture, processing or preservation of foods, and because they are taken daily with food for a long time, their safety should be ensured.
  • the Food Additives Code of the Food Sanitation Act (KFDA Notification, Food Additives Standards and Standards) defines the food additives, which are guaranteed to be safe, divided into chemical synthetics, natural additives, and mixed preparations.
  • These food additives may be divided into sweeteners, flavors, preservatives, emulsifiers, acidulants, thickeners, and the like in terms of their functionalities.
  • Sweeteners are used to impart a proper sweetness to foods, and may be natural or synthesized.
  • a natural sweetener is used.
  • sugar sweeteners such as corn syrup solids, honey, sucrose, fructose, lactose and maltose.
  • Flavoring agents can be used to enhance the taste or aroma, both natural and synthetic. It is the case of using a natural thing preferably.
  • the natural flavor may be obtained from apples, lemons, citrus fruits, grapes, strawberries, peaches, and the like, or may be obtained from green tea leaves, round leaves, jujube leaves, cinnamon, chrysanthemum leaves, jasmine and the like.
  • ginseng red ginseng
  • bamboo shoots aloe vera, ginkgo and the like can be used.
  • Natural flavors can be liquid concentrates or solid extracts.
  • synthetic flavoring agents may be used, and synthetic flavoring agents may include esters, alcohols, aldehydes, terpenes, and the like.
  • Sodium sorbate, sodium sorbate, potassium sorbate, calcium benzoate, sodium benzoate, potassium benzoate, EDTA (ethylenediaminetetraacetic acid), etc. may be used as a preservative, and as an emulsifier, acacia gum, carboxymethylcellulose, xanthan gum, Pectin etc. can be mentioned, As acidic acid, acid, malic acid, fumaric acid, adipic acid, phosphoric acid, gluconic acid, tartaric acid, ascorbic acid, acetic acid, phosphoric acid, etc. can be used.
  • the acidulant may be added so that the food composition is at an appropriate acidity for the purpose of inhibiting the growth of microorganisms in addition to the purpose of enhancing the taste.
  • suspending implementers As the thickener, suspending implementers, sedimenting agents, gel formers, swelling agents and the like can be used.
  • the food composition of the present invention may include a bioactive substance or minerals known in the art for the purpose of supplementing and reinforcing the functionality and nutritional properties and ensuring the stability as a food additive.
  • physiologically active substances include catechins, vitamin B1, vitamin C, vitamin E, vitamin B12 and the like, tocopherol, dibenzoylthiamine, and the like contained in green tea.
  • minerals include calcium preparations such as calcium citrate and magnesium stearate.
  • Magnesium preparations such as iron, iron preparations such as iron citrate, chromium chloride, potassium iodine, selenium, germanium, vanadium, zinc and the like.
  • the food additive as described above may be included in an amount that can achieve the purpose of addition according to the product type.
  • compositions for improving meningioma including salidroside and / or betulin as an active ingredient.
  • the composition of the present invention uses salidroside and / or betulin having cytotoxicity against HBL-52 cells, which are human-derived meningioma cell lines, as an active ingredient, and may be commercialized as drugs or foods (particularly health functional foods).
  • Fig. 2 shows the results of cell proliferation inhibition of betulin's meningioma cells.
  • Figure 3 shows the results of cell proliferation inhibition evaluation of the meningioma cells of the salidroside and betulin mixture.
  • HBL-52 a human meningioma cell line
  • DMEM medium containing 10% FBS, 1% Penicillin-Streptomycin fetal bovine serum
  • MCO-20AIC 5% CO 2 incubator
  • the cells were collected, placed in a centrifuge tube, and centrifuged (1,000 rpm, 5 minutes). After centrifugation, the supernatant was removed and a new complete medium was added to the pellet to make cell suspension.
  • the cells were dispensed 200 ⁇ L into each well of a 96 well plate at a concentration of 5 ⁇ 10 4 cells / 200 ⁇ L and incubated for 24 hours in a 37 ° C., 5% CO 2 incubator.
  • the experimental group consisted of a single salidroside (test substance 1), a single betulin (test substance 2), and a mixed salidroside and betulin (test substance 3, the mixing ratio is weight ratio).
  • Test substance 1 a single salidroside
  • test substance 2 a single betulin
  • test substance 3 a mixed salidroside and betulin
  • Table 1 Table 1
  • Test substance Test substance concentration ( ⁇ g / ml) Processing liquid volume (Ml / well)
  • Test substance 1 100, 50, 25, 12.5, 6.25, 3.125, 1.56, 0.78, 0.39, 0 0.2
  • Test substance 2 100, 50, 25, 12.5, 6.25, 3.125, 1.56, 0.78, 0.39, 0 0.2
  • Test substance 3 50/50, 25/25, 12.5 / 12.5, 6.25 / 6.25, 3.125 / 3.125, 1.56 / 1.56, 0.78 / 0.78, 0.39 / 0.39, 0.19 / 0.19, 0 0.2
  • the cell survival rate was calculated by substituting the absorbance of the wells treated with the test substance for each concentration into the following formula.
  • IC 50 a concentration that inhibits cell proliferation by 50%, was evaluated using regression analysis.
  • the degree of inhibition of cell proliferation in the treatment of negative controls was 0.0%
  • the degree of inhibition of cell proliferation by concentration of each test substance 2 (betulin) is shown in FIG. 2.
  • the degree of inhibition of cell proliferation was 0.0, 3.7, 7.1, 8.9, 33.4, 48.5, 51.4, 66.9, 92.0 and 93.8%, with an IC 50 of 8.8 ⁇ g / mL.
  • the degree of inhibition of cell proliferation by concentration of each test substance 3 is shown in FIG. 3.
  • the test material 3 is 0, 0.19 / 0.19, 0.39 / 0.39, 0.78 / 0.78, 1.56 / 1.56, 3.125 / 3.125, 6.25 / 6.25, 12.5 / 12.5, 25/25, 50/50 ⁇ g / mL
  • Treatment with each concentration resulted in inhibition of cell proliferation of 0.0, 11.5, 13.6, 37.3, 60.0, 83.1, 89.2, 90.6, 91.6 and 92.1%, and IC 50 was calculated to be 2.3 ⁇ g / mL.
  • cell proliferation was evaluated in the experiments using HBL-52, a human-derived meningioma cell line, to evaluate the cytotoxicity of test substance 1, salivaside, test substance 2, betulin, test substance 3, salidroside, and betulin.
  • IC 50 the concentration that inhibit 50% respectively 25.2, 8.8, appears to 2.3 ⁇ g / mL appear to have cell proliferation inhibitory effect IC 50 of the test substance 3 is combined in a single material than when viewed at a lower point than the single treatment groups The result shows that it works.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pour soulager le méningiome, contenant, en tant que principe actif, du salidroside et/ou de la bétuline, qui est cytotoxique pour les cellules HBL-52, les cellules HBL-52 étant des lignées cellulaires de méningiome d'origine humaine.
PCT/KR2019/003096 2018-05-25 2019-03-18 Composition pour soulager le méningiome en utilisant le salidroside et la bétuline WO2019225845A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2018-0059923 2018-05-25
KR1020180059923A KR101909885B1 (ko) 2018-05-25 2018-05-25 살리드로사이드 또는 베툴린을 이용한 뇌수막종 개선용 조성물

Publications (1)

Publication Number Publication Date
WO2019225845A1 true WO2019225845A1 (fr) 2019-11-28

Family

ID=64102128

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/003096 WO2019225845A1 (fr) 2018-05-25 2019-03-18 Composition pour soulager le méningiome en utilisant le salidroside et la bétuline

Country Status (2)

Country Link
KR (1) KR101909885B1 (fr)
WO (1) WO2019225845A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101909885B1 (ko) * 2018-05-25 2018-10-19 김예원 살리드로사이드 또는 베툴린을 이용한 뇌수막종 개선용 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11502525A (ja) * 1995-03-21 1999-03-02 ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 悪性黒色腫の成長を阻害するためのベツリン酸とその誘導体の使用およびこれをモニターする方法
KR20010080507A (ko) * 1998-11-18 2001-08-22 추후보정 신규한 베툴린산 유도체, 그의 제조 방법 및 암 성장억제제로서의 그의 용도
JP2006517208A (ja) * 2003-02-11 2006-07-20 ノベリックス・ファーマシューティカルズ・インコーポレイテッド 腫瘍増殖を阻害するための医薬
KR20100119232A (ko) * 2009-04-30 2010-11-09 강원대학교산학협력단 세포 독성이 감소된 홍경천의 유합조직의 생산 방법 및 그 추출물
KR20140104037A (ko) * 2011-12-16 2014-08-27 글락소스미스클라인 엘엘씨 베툴린의 유도체
KR101909885B1 (ko) * 2018-05-25 2018-10-19 김예원 살리드로사이드 또는 베툴린을 이용한 뇌수막종 개선용 조성물

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11502525A (ja) * 1995-03-21 1999-03-02 ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 悪性黒色腫の成長を阻害するためのベツリン酸とその誘導体の使用およびこれをモニターする方法
KR20010080507A (ko) * 1998-11-18 2001-08-22 추후보정 신규한 베툴린산 유도체, 그의 제조 방법 및 암 성장억제제로서의 그의 용도
JP2006517208A (ja) * 2003-02-11 2006-07-20 ノベリックス・ファーマシューティカルズ・インコーポレイテッド 腫瘍増殖を阻害するための医薬
KR20100119232A (ko) * 2009-04-30 2010-11-09 강원대학교산학협력단 세포 독성이 감소된 홍경천의 유합조직의 생산 방법 및 그 추출물
KR20140104037A (ko) * 2011-12-16 2014-08-27 글락소스미스클라인 엘엘씨 베툴린의 유도체
KR101909885B1 (ko) * 2018-05-25 2018-10-19 김예원 살리드로사이드 또는 베툴린을 이용한 뇌수막종 개선용 조성물

Also Published As

Publication number Publication date
KR101909885B1 (ko) 2018-10-19

Similar Documents

Publication Publication Date Title
KR101406201B1 (ko) 인제난 타입의 디테르펜 화합물 및 이를 포함하는 바이러스 감염 질환의 치료 또는 예방용 약학적 조성물
KR102182733B1 (ko) 복분자 미성숙과 추출물을 유효성분으로 포함하는 항산화 및 항염증용 조성물
JP2012051940A (ja) ビワ葉抽出物を含有する飲食品及び医薬品
EP2990047B1 (fr) Composition pour prévenir, soulager ou traiter la colite, contenant des extraits complexes
KR102134307B1 (ko) 안토시아닌-후코이단 복합체를 유효성분으로 함유하는 면역증강제, 면역항암제 및 항암제 부작용 완화제
KR102519649B1 (ko) 캠퍼롤 및 에피카테킨 갈레이드를 포함하는 홍경천 추출물을 포함하는 전립선 관련 질환의 예방 또는 치료용 조성물
WO2017003086A1 (fr) Composition permettant d'inhiber et de prévenir la myopathie, contenant un extrait de feuilles de haricot en tant que principe actif
WO2019225845A1 (fr) Composition pour soulager le méningiome en utilisant le salidroside et la bétuline
KR101445966B1 (ko) 백두구 추출물을 포함하는 항비만 조성물
US20240115644A1 (en) Composition for preventing, improving or treating gastritis or peptic ulcer comprising extract of cinnamomum cassia, fraction of said extract, isolate of said fraction or compounds isolated therefrom
WO2022010219A1 (fr) Composition pour soulager la fibrose pulmonaire à l'aide de 4',6,7-triméthoxyisoflavone et de catéchol
WO2017142371A1 (fr) Composition contenant un extrait de phragmitis rhizoma en tant que principe actif servant à prévenir, améliorer ou traiter une maladie attribuée à un effet secondaire d'agent anticancéreux
WO2021235637A1 (fr) Composition pour la prévention, la réduction des symptômes ou le traitement d'une maladie respiratoire
WO2020122373A1 (fr) Composition comprenant un extrait de glycyrrhiza uralensis en tant que principe actif pour la prévention, l'atténuation ou le traitement du syndrome d'hypogonadisme d'apparition tardive
KR101971986B1 (ko) 참나무겨우살이 추출물을 유효성분으로 포함하는 항암용 조성물
KR101028864B1 (ko) 배무채로부터 설포라펜을 분리하는 방법 및 이의 용도
KR20140044223A (ko) 자외선을 처리한 벼 추출물을 유효성분으로 포함하는 대장암 예방 또는 치료용 약학적 조성물
WO2021162505A1 (fr) Composé isolé à partir de torilidis fructus et composition pharmaceutique anticancéreuse le contenant en tant que principe actif
US20200046728A1 (en) Composition comprising oleanolic acid acetate as active ingredient for preventing, alleviating, or treating renal toxicity induced by medicine
WO2018056772A1 (fr) Composition antitumorale ou composition induisant une immunité antitumorale comprenant un extrait d'erysimum sp. en tant qu'ingrédient efficace
WO2022260211A1 (fr) Composition comprenant de l'extrait d'agastache rugosa et son utilisation pour l'amélioration de la fonction musculaire ou la prévention, le soulagement ou le traitement de maladies musculaires
KR102311887B1 (ko) 괭생이모자반 추출물을 유효성분으로 포함하는 간질환 예방 또는 치료용 약학적 조성물
EP4151226A1 (fr) Agent thérapeutique contre le coronavirus comprenant un extrait de feuille de zanthoxylum piperitum en tant que principe actif
KR20180109156A (ko) 모과 추출물을 포함하는 항염증성 및 염증성 신경퇴행성 질환 예방 또는 치료용 조성물
KR20170106627A (ko) 프로토파낙사디올류 진세노사이드 화합물을 포함하는 교모세포종 치료 및 전이 억제용 약학 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19807080

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19807080

Country of ref document: EP

Kind code of ref document: A1